Terpenes & Minor Cannabinoids
Scientists employed by the US government filed a patent in 2001 for cannabinoids as antioxidants and neuroprotectants, citing their potential for treating Alzheimer’s disease among others.
Most cannabis supplied by the U.S. government for research has less than 10% THC and it may have been stored for more than a year.
Unbalanced cannabinoid tone appears to play a role in chronic kidney disease, with CB1 receptors overactivated and CB2 receptors dificient.
Project CBD discusses the benefits of CBD, the "entourage effect" and the microbiome with Dr. Ethan Russo.
The health benefits of many common kitchen spices are mediated by the same cannabinoid receptors in the brain and body that cannabis activates.
Low-dose and high-dose treatments, protocols for chronic users, and the potential benefits of psychoactivity.
Dr. Bonni Goldstein discusses using cannabis medicine in her practice for patients with intractable epilepsy, cancer, autism, and mental health conditions.
Dr. Ethan Russo gives a talk at the quarterly Society of Cannabis Clinicians meeting on minor cannabinois and terpenes.
Learn about the aromatic compounds that give cannabis its distinct smell and make each strain unique.
THC has been the focus of cannabis research since 1964. Today, the contributions of CBD and terpenes are being scientifically demonstrated.
THE ESSENTIAL GUIDE TO CBD
By the Editors of Reader’s Digest & Project CBD: Everything You Need to Know About What It Helps, Where to Buy It, and How to Take It.